BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 29212856)

  • 1. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
    Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
    Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 4. MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.
    Bobustuc GC; Smith JS; Maddipatla S; Jeudy S; Limaye A; Isley B; Caparas ML; Constantino SM; Shah N; Baker CH; Srivenugopal KS; Baidas S; Konduri SD
    Mol Med; 2012 Sep; 18(1):913-29. PubMed ID: 22549111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK.
    Si X; Zang R; Zhang E; Liu Y; Shi X; Zhang E; Shao L; Li A; Yang N; Han X; Pan B; Zhang Z; Sun L; Sun Y
    Oncotarget; 2016 Dec; 7(49):81452-81462. PubMed ID: 27845892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
    Selmin OI; Donovan MG; Skovan B; Paine-Murieta GD; Romagnolo DF
    Int J Oncol; 2019 Mar; 54(3):869-878. PubMed ID: 30664189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.
    Zhang J; Zhou C; Jiang H; Liang L; Shi W; Zhang Q; Sun P; Xiang R; Wang Y; Yang S
    Cell Death Dis; 2017 Apr; 8(4):e2732. PubMed ID: 28383555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transcriptional co-activator NCOA6 promotes estrogen-induced GREB1 transcription by recruiting ERα and enhancing enhancer-promoter interactions.
    Tong Z; Liu Y; Yu X; Martinez JD; Xu J
    J Biol Chem; 2019 Dec; 294(51):19667-19682. PubMed ID: 31744881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
    Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
    Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
    PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells.
    Wang L; Sun J; Yin Y; Sun Y; Ma J; Zhou R; Chang X; Li D; Yao Z; Tian S; Zhang K; Liu Z; Ma Z
    Cell Death Dis; 2021 Feb; 12(2):149. PubMed ID: 33542201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Estrogen-Regulated
    Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
    Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
    Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
    Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
    Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines.
    Williams KE; Anderton DL; Lee MP; Pentecost BT; Arcaro KF
    Epigenetics; 2014 Feb; 9(2):297-307. PubMed ID: 24225485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody.
    Hnatyszyn HJ; Liu M; Hilger A; Herbert L; Gomez-Fernandez CR; Jorda M; Thomas D; Rae JM; El-Ashry D; Lippman ME
    Breast Cancer Res Treat; 2010 Jul; 122(2):371-80. PubMed ID: 19842031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.
    Si X; Liu Y; Lv J; Ding H; Zhang XA; Shao L; Yang N; Cheng H; Sun L; Zhu D; Yang Y; Li A; Han X; Sun Y
    Oncotarget; 2016 Apr; 7(15):20966-80. PubMed ID: 26980709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
    Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
    Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.